Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
06 March 2020 | Story Ruan Bruwer | Photo Supplied
Nomsa Mathontsi
Nomsa Mathontsi has been training with the South African senior women’s football team since Monday (03/02).

Whether she takes to the field or not, being part of the senior national women’s soccer team is already an accomplishment, says Nomsa Mathontsi. 

The BAdmin student in Economic and Management Sciences has been chosen for the Banyana Banyana squad for the first time. They face Lesotho on Sunday, 8 March 2020 in an international friendly in Johannesburg. There could be two Kovsies on the field, as Mating Monokoane, another University of the Free State student, was selected for Lesotho’s team. Both of them are midfielders.

The 21-year-old Mathontsi, who has been part of the Kovsie football team since 2018, says it will be a dream come true for her to wear the national colours. “Even if I don't get to play, I will still be proud of myself for being able to take on the challenge of going to camp and giving myself a chance to show my talent.”

“We have been together since Monday, 2 March 2020 and it has been the best experience, especially the fact that football has put me in the high-performance centre (South African Football Association girls’ academy), and now I get an opportunity to be with Banyana for the first time.”

“I was shocked when I got the call, but excited to face the challenge because it's never easy to get a call-up to Banyana, you need to work for it,” she says.

According to Mathontsi, who grew up in Mamelodi, Pretoria, her first love was athletics, but that changed during the 2010 World Cup in South Africa.
“I was an athlete back in primary school and it just so happened that I was selected to play football, which I never really enjoyed. I also had the opportunity to be part of the 2010 FIFA World Cup ceremonies, where I developed a love for football.”

News Archive

Heart-valve studies receive international recognition
2017-07-11

 Description: Heart-valve studies  Tags: Heart-valve studies  

Prof Francis Smit, Head of the Department of
Cardiothoracic Surgery at the UFS, and Manager of the
Robert WM Frater Cardiovascular Research Centre, with
Kyle Davis, Mechanical Engineer at the centre.

Photo: Rulanzen Martin

Three heart-valve studies which have been developed at the Robert WM Frater Cardiovascular Research Centre at the School of Medicine at the University of the Free State (UFS) were recently presented in Monte Carlo at the conference of the prestigious global Heart Valve Society (HVS).

These studies are all headed by Prof Francis Smit, Head of the Department of Cardiothoracic Surgery at the UFS, and Manager of the Robert WM Frater Cardiovascular Research Centre.
Prof Smit says the HVS is a combination of the former heart-valve societies of Europe and the US. “Studies on heart-valve disease, heart-valve-related products and operations, as well as the design and development of new valves were presented. There are both clinical and development divisions.

He says the study in which the hemodynamics of their redesigned mechanical poppet valve was compared to a commercial bi-leaflet mechanical heart valve, was named as the best poster presentation in the experimental valve development and numerical flow dynamics division. The study, which was presented by Kyle Davis, mechanical engineer at the centre, competed against some of the best heart-valve research units in the world.

The redesigned valve, based on the 1960s Cape Town poppet valve, has the potential to provide a low-cost solution for mechanical heart-valve replacement. It is possible to produce the titanium ring with 3-D printers and is, together with the silicon poppet valve, extremely inexpensive compared to current mechanical valve-manufacturing processes.
The advantages of this valve over current mechanical valves is that, due to the effective and laminar flow characteristics, as well as the simple locking mechanisms, there is a reduced chance of valve thrombosis, and the need for anti-clotting drugs is therefore limited.

It was also confirmed that the new valve more than meets the published FDA (Federal Drug Agency) requirements, which determine the minimum standards of valves for human use in the US.

The redesigned valve also has a very low platelet activation impact, which is responsible for platelet thrombosis and leads to valve thrombosis or strokes. This valve is another heart-valve project by the centre, which is also in the process of evaluating a tri-leaflet polyurethane valve developed by them.


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept